# OnCo record alphamedix-02 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/alphamedix-02/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "alphamedix-02", "NCT05153772" ;
  schema:name "ALPHAMEDIX-02"@en ;
  schema:description "An alpha-emitting radioligand met all its primary endpoints, with responses in more than half of patients new to radioligand therapy."@en ;
  schema:url <https://onco.cc/trials/alphamedix-02/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05153772>, <https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-08-05-00-00-3163053> ;
  onco:status "positive" ;
  onco:phase "2" ;
  schema:startDate "2021-12-21" ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/> ;
  onco:technologies <https://onco.cc/technologies/targeted-alpha-therapy/>, <https://onco.cc/technologies/prrt/> ;
  onco:drugs <https://onco.cc/drugs/alphamedix/> ;
  onco:companies <https://onco.cc/companies/radiomedix/>, <https://onco.cc/companies/orano-med/>, <https://onco.cc/companies/sanofi/> .